Dr Reddys Laboratories Ltd management interview: Dr Reddy’s Q2 Profit Falls 36% As Lower Lenalidomide Sales Hit US Business
Business Today, 2026-10-26. Video: https://www.youtube.com/watch?v=VDks552eBVs
- Margin outlook: Quarter two delivered double-digit growth and 20% EBITDA; management aims to sustain 20% EBITDA in the base business, with an aspiration to reach 25% as complex products and biosimilars scale.
- US generics: The US base business grew through new products and volume, with quarter-two price erosion at a single-digit level. Priorities include first-to-market launches, cost management, biosimilars and consumer health; rituximab is approved in the US, and the company is awaiting results for abatacept.
- India growth: Revenue grew 17%, driven by volume, new products and price increases. Management expects healthy growth, supported by branded generics, innovative assets, consumer health and acquisitions.
- Semaglutide supply: After resolving API scale-up issues, the company is validating the formulation and expects supply to resume in the middle of November if validation succeeds. It has 10 approvals in various countries other than Canada and India, and expects to sell 6 to 7 million pens in quarter three and quarter four.
- Growth investments: Management identified biosimilars, peptides, innovative assets and consumer health as growth levers, and expects R&D spending to be between 7 to 8%. Aurigene’s pharmaceutical services business could reach 3x its current size over the next couple of years.